Summary: The results of the combination VAD (vincristin, adriamycin and dexamethason) in 10 patients resistant after the primary therapy are presented. In 7 cases a favourable reponse with decrease of paraprotein was achieved. The survival time untill now is 11.3 month when 6 patients are still alive.
The combined chemotherapy with vincristin-adriamycin-dexamethason in patients with resistant and recurrent multiple myeloma
